The studied cohort included 38 patients aged <12 months; 34 of them had a normal MYCN status and all were treated in accordance with the therapeutic guidelines of an ad hoc SIOPEN (International Society of Paediatric Oncology Europe Neuroblastoma) protocol [21]. The gene discussed is MYCN; the disease is neuroblastoma.